Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLC

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Friday,Benzinga reports. They presently have a $6.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 184.36% from the company’s current price.

Several other equities analysts also recently weighed in on the company. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday.

Esperion Therapeutics Stock Down 17.3 %

NASDAQ ESPR traded down $0.44 during trading on Friday, hitting $2.11. The stock had a trading volume of 19,409,808 shares, compared to its average volume of 6,323,658. The company has a market capitalization of $415.75 million, a PE ratio of -3.30 and a beta of 1.01. The firm has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.22. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Boomfish Wealth Group LLC grew its position in shares of Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares in the last quarter. Summit Financial LLC boosted its holdings in Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 6,823 shares in the last quarter. National Bank of Canada FI boosted its holdings in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 11,658 shares in the last quarter. Finally, BOKF NA acquired a new position in Esperion Therapeutics in the second quarter valued at approximately $26,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.